Clinical Trial to Evaluate the Efficacy and Safety of UNI-DEB for Unresectable Hepatocellular Carcinoma

NACompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

October 25, 2017

Primary Completion Date

June 30, 2018

Study Completion Date

September 3, 2018

Conditions
Hepatocellular Carcinoma Non-resectable
Interventions
DEVICE

UNI-DEB

Applicate the TACE with UNI-DEB to unresectable hepatocellular carcinoma patient

Trial Locations (8)

Unknown

Chonnam National University Hospital, Gwangju

Seoul National University Bundang Hospital, Gyeonggi-do

The Catholic University of Korea, Uijeongbu ST. Mary's Hospital, Gyeonggi-do

Inha University Hospital, Incheon

Pusan National University Hospital, Pusan

Seoul National University Hospital, Seoul

Severance Hospital, Seoul

The Catholic University of Korea, Seoul ST. Mary's Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Jeil Pharmaceutical Co., Ltd.

INDUSTRY

NCT03533920 - Clinical Trial to Evaluate the Efficacy and Safety of UNI-DEB for Unresectable Hepatocellular Carcinoma | Biotech Hunter | Biotech Hunter